Janssen reports positive results from Phase III darunavir-based HIV regimen trial

Janssen-Cilag International has reported positive results from a Phase III clinical trial (EMERALD) of darunavir containing a single-tablet regimen (STR) in patients with human immunodeficiency virus type 1 (HIV-1).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news